Drugs and Devices
by Jenna Ogilvie | Jun 22, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Feb 26, 2015 | Commentary, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Feb 19, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Feb 12, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Jenna Ogilvie | Jan 29, 2015 | Discussion Paper, Perspectives
The types of evidence needed to support the use of genome sequencing in the clinic varies by stakeholder and circumstance. In this IOM series, seven individually authored commentaries explore this important issue, discussing the challenges involved in and...
by Laura DeStefano | Mar 22, 2013 | Commentary, Perspectives
Support for core public health capacity is diminishing; outbreaks of microbial threats are not. In 2012 there were a number of high-profile threats (see the box below) that demanded public health intervention to protect the public. It is well understood that the role...
by Laura DeStefano | Feb 7, 2013 | Commentary, Perspectives
The first test of penicillin on a human, Constable Albert Alexander in 1941, illustrated the remarkable power of antibiotics to control bacterial infection, only to end in tragedy when all available penicillin was exhausted and Alexander’s infection recrudesced...
by Laura DeStefano | May 18, 2012 | Discussion Paper, Perspectives
In Canada, as elsewhere, the translation of health research outcomes to development of products and services for health care and final implementation in patients does not progress as rapidly, efficiently, or successfully as it should. In order to address this problem,...
by Laura DeStefano | May 18, 2012 | Discussion Paper, Perspectives
Introduction Traditional randomised clinical trials are very expensive and time-consuming and often have poor external validity (Ware and Hamel, 2011). The challenge for modern medicine is to find ways of producing good-quality evidence with good external validity and...
by Laura DeStefano | May 18, 2012 | Discussion Paper, Perspectives
The arrangements for the regulation and governance of health research in the United Kingdom (UK) have evolved, piecemeal, over the past 30 years, and much is now enshrined in UK and European Union (EU) legislation. Each individual measure was introduced with the best...
